History | Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 152 KB)

Published:

26 July 2023
Register of interests (PDF 278 KB)

Published:

26 July 2023

Final draft guidance

Final draft guidance
Final draft guidance (PDF 267 KB)

Published:

22 June 2023
Committee papers (PDF 9.15 MB)

Published:

22 June 2023
Public committee slides (PDF 1.11 MB)

Published:

22 June 2023
Final appraisal document Equality Impact Assessment (PDF 152 KB)

Published:

22 June 2023
Final draft guidance Managed Access Agreement (PDF 389 KB)

Published:

22 June 2023

Invitation to participate

Final scope (PDF 207 KB)

Published:

14 July 2022
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 224 KB)

Published:

14 July 2022
Equality impact assessment (Scoping) (PDF 121 KB)

Published:

14 July 2022
Final stakeholder list (PDF 189 KB)

Published:

14 July 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft matrix post referral (PDF 187 KB)

Published:

11 April 2022
Draft scope post referral (PDF 239 KB)

Published:

11 April 2022